Patents Assigned to Pfizer Inc.
  • MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY
    Publication number: 20230165977
    Abstract: The present disclosure relates to recombinant nucleic acids and gene therapy vectors comprising a modified nucleic acid encoding aspartoacylase (ASPA), and variants thereof, for use in the treatment of diseases and disorders associated with a deficiency or dysfunction of ASPA, and in particular, Canavan disease.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Paola Leone, Jeremy Francis, Basel T. Assaf, Shoh Asano, Kathrine Hales, Allison P. Berg
  • SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF
    Publication number: 20230167069
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
  • BCKDK INHIBITORS AND/OR DEGRADERS
    Publication number: 20230167080
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.
    Type: Application
    Filed: November 30, 2022
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Leanne Marie BUZON, Kimberly O'Keefe CAMERON, Kevin Francis DEBOYACE, Kevin James FILIPSKI, David Andrew GRIFFITH, Bethany Lyn KORMOS, Shenping LIU, Luis Angel MARTINEZ ALSINA, Matthew Richard REESE, Rachel Jane ROTH FLACH, Yuan ZHANG
  • Benzimidazole derivative compounds and uses thereof
    Patent number: 11661419
    Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: May 30, 2023
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • Purification of antibody drug conjugates using a sodium phosphate gradient
    Patent number: 11661438
    Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 30, 2023
    Assignee: Pfizer, Inc.
    Inventors: Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
  • Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
    Publication number: 20230157998
    Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 25, 2023
    Applicant: Pfizer Inc.
    Inventors: Padmavani Bezawada, Benjamin Joseph Burke, Emma Louise Hawking, Robert Louis Hoffman, Robert Steven Kania, Jonathan Richard Lillis, Matthew Nathan O'Brien Laramy, Klimentina Dimitrova Pencheva, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst
  • CRYSTALLINE FORMS OF 3-CYANO-1-[4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL]-1H-PYRAZOL-1-YL]CYCLOBUTANEACETONITRILE, AND USE THEREOF
    Publication number: 20230159539
    Abstract: The present invention discloses novel crystalline forms of (1R,3R)-3-(cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile, Form 1 anhydrous free base and Form 2 monohydrate, pharmaceutical composition containing them, preparations thereof and uses thereof.
    Type: Application
    Filed: April 5, 2021
    Publication date: May 25, 2023
    Applicant: PFIZER INC.
    Inventor: Andrew James JENSEN
  • CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS
    Publication number: 20230158034
    Abstract: The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.
    Type: Application
    Filed: April 7, 2021
    Publication date: May 25, 2023
    Applicants: Pfizer Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Mansi Arora, Stephen George Dann, Nichol Lee Goodman Miller, Sabrina Spencer, Todd Lee VanArsdale
  • Aminopyrimidinyl derivatives
    Patent number: 11655252
    Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen or hydroxy; wherein R1 and R2 are not both hydroxy. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: May 23, 2023
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Wenhua Jiao, Manjinder Singh Lall, Ricardo Lira, Mark Edward Schnute
  • Methods of Treating Coronavirus Disease 2019
    Publication number: 20230149407
    Abstract: The present invention is related to the discovery of new methods for treating the pathologic inflammatory response associated with patients infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment a therapeutically effective amount of a JAK inhibitor, a JAK/TYK inhibitor, or an IRAK4 inhibitor, or a combination thereof.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 18, 2023
    Applicant: Pfizer Inc.
    Inventors: Michael Corbo, Spencer Ian Danto, Tamas Andras Koncz, Elena Peeva, Hernan Valdez, V, Michael Steven Vincent, Cara Margaret May Williams
  • TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
    Publication number: 20230146535
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Application
    Filed: October 12, 2022
    Publication date: May 11, 2023
    Applicant: PFIZER INC.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • ANTI-GUCY2C ANTIBODIES AND USES THEREOF
    Publication number: 20230146072
    Abstract: The present invention is directed to antibodies that specifically bind to GUCY2c and methods of using such antibodies in the diagnosis and/or treatment of cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: May 11, 2023
    Applicant: PFIZER INC.
    Inventors: Chew Shun CHANG, Divya MATHUR, Adam Reid ROOT
  • Boron Containing PDE4 Inhibitors
    Publication number: 20230148402
    Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z ??Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
    Type: Application
    Filed: December 15, 2022
    Publication date: May 11, 2023
    Applicant: Pfizer Inc.
    Inventors: Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Joseph Walter Strohbach, Rubben Federico Torella, Thean Yeow Yeoh, Yasheen Zhou
  • Melanocortin 4 receptor antagonists and uses thereof
    Patent number: 11643412
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
    Publication number: 20230134160
    Abstract: The invention relates to a method of preparing a protein formulation including a therapeutic protein, the method comprising the steps of: providing a solution comprising said protein; concentrating the protein in the solution by a first ultra-filtration step; diafiltering the solution with a diafiltration buffer including at least one first excipient, whereby a retentate is obtained comprising the protein and the first excipient; further concentrating the protein in the retentate by a second ultra-filtration step; and adding at least one final excipient, whereby the protein formulation with a desired protein concentration is obtained. According to the inven tion, the method further comprises, before the second ultra-filtration step, adding a second excipient to the retentate obtained from the diafiltration step. The invention is also directed to antibody formulations produced by the foregoing method.
    Type: Application
    Filed: September 8, 2016
    Publication date: May 4, 2023
    Applicant: PFIZER INC.
    Inventors: Judy Kay GLYNN, Brian Xin CHEN, Daniel Patrick LACASSE
  • Pharmaceutical compounds
    Patent number: 11634425
    Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, -a- and -c- are bonds, and -b- and -d- are absent; or (ii) T is C, Z is N, -b- and -d- are bonds, and -a- and -c- are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7—COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: April 25, 2023
    Assignee: PFIZER INC.
    Inventors: George Stuart Cockerill, James Good, Edward James Cochrane
  • Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
    Patent number: 11634410
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 11634504
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Compounds and Method of Treating COVID-19
    Publication number: 20230120707
    Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound
    Type: Application
    Filed: March 31, 2021
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
  • GLP-1 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20230124938
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri